Rising Prevalence of Allergic Reactions to Propel Global Food Allergy Diagnostics & Therapeutics Market

  • Food allergy is a type of immune response to food, which may range from mild to severe in intensity. Food allergies are classified into three key types: IgE-mediated food allergy, non-IgE-mediated food allergy, and mixed IgE & non-IgE-mediated food allergy.
  • As per the Asthma and Allergy Foundation of America, approximately 26 million adults (i.e. 10.8%) in the U.S. have food allergies and 5.6 million of children (i.e. 7.6%) suffer from a kind of food allergy. According to LEAPSMAG, the number of emergency room visits for chronic conditions of allergic reactions or anaphylaxis in the U.S. nearly doubled from 2010 to 2016. In the U.S., about 90% of allergic reactions arise from the following eight foods: milk, eggs, peanuts, tree nuts, soy, wheat, fish, and shellfish.

Read Report Overview: https://www.transparencymarketresearch.com/food-allergy-diagnostics-therapeutics-market.html

Key Drivers and Restraints of Global Food Allergy Diagnostics & Therapeutics Market

  • Increasing prevalence of food allergy across the globe is boosting the global market for food allergy diagnostics & therapeutics. According to data published by World Allergy Organization in 2017, the rate of prevalence of peanut allergy among children in the U.K., North America, and Australia has doubled over the last 10 years and it is approximately 1.8%, 1.4%, and 3.0%, respectively, in these countries.
  • Technological advancements and increase in the number of R&D initiatives taken by various pharmaceutical companies also fuel the global market. In September 2019, Aimmune Therapeutics, Inc. announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food & Drug Administration (FDA) had voted to support the use of AR101 (proposed trade name: PALFORZIA) in children and teens with peanut allergy. With the help of epinephrine auto-injector, which is a type of auto-injector used for the treatment of peanut allergy or allergy to bee sting, these allergies can be easily treated.
  • However, high costs of a few drugs such as EpiPen (which is USD 630) make these drugs unaffordable for people in low-income countries

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75541

Therapeutic Segment to Witness Significant Growth

  • Based on product type, the global food allergy diagnostics& therapeutics market can be divided into 2D diagnostics and therapeutics
  • The therapeutic segment dominated the global market, in terms of revenue, in 2018. Rising awareness among patients about various modalities of managing food allergy boosts the therapeutic segment. This segment can be sub-segmented into antihistamines, epinephrine auto-injector, and others.
  • On the other hand, the diagnosis segment can be sub-segmented into ImmunoCAP test, skin prick food allergy test, and others

Peanuts to Witness High Demand

  • In terms of source, the global food allergy diagnostics & therapeutics market can be categorized into eggs, milk, peanuts, tree nuts, fish, shellfish, wheat, soy, and others
  • Peanuts including almonds, cashews, and walnuts is one of the most common sources of food allergy. Allergy to cow’s milk is the most common food allergy among infants and young children. As per the data published in Intellisphere, LLC in 2018, around 1.25 million people or 2.2% of all children and adults suffered from peanut allergy.
  • As per the JAMA Network Open journal, approximately 23.8 million adults were affected by shellfish, milk, peanut, tree nut, and fin fish allergy in the U.S. in 2019

Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75541

Diagnostic Laboratories Segment to Witness Significant Growth

  • Based on end-user, the global food allergy diagnostics & therapeutics market can be divided into academic research institutes, hospitals & clinics, and diagnostics laboratories
  • The hospitals & clinics segment is expected to hold the maximum share of the global market between 2019 and 2027. Rising prevalence of allergy along with increasing number of hospitalization cases is estimated to boost the segment.
  • The diagnostic laboratories segment is expected to expand at the maximum CAGR during the forecast period, due to extensive usage of allergy diagnostic kits in disease diagnosis. Increasing number of diagnostic centers is also fueling the segment.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75541

North America to Dominate Global Food Allergy Diagnostics & Therapeutics Market

  • In terms of region, the global food allergy diagnostics & therapeutics market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • In terms of revenue, North America dominated the global food allergy diagnostics & therapeutics market, followed by Europe, in 2018. Researchers estimate that 32 million people in the U.S. suffer from food allergies, including 5.6 million children aged 18 years or below. As per the Food Allergy Research & Education, about 40% children in the country are suffering from allergies from more than one food. According to European Academy of Allergy and Clinical Immunology, more than 17 million people in Europe suffer from food allergy, among which 3.5 million people are aged below 25 years.
  • However, the food allergy diagnostics & therapeutics market in Asia Pacific is expected to expand at a rapid CAGR during the forecast period, owing to the increasing prevalence of food allergy along with government support for production of new biologicsin the region. Investments by various companies to expand their presence as well as product portfolios also boost the market in the region.

Key Manufacturers Operating in Global Market

The global food allergy diagnostics & therapeutics market was highly fragmented in 2018. Key manufacturers operating in the global market are:

  • Allergy Therapeutics
  • Immunomic Therapeutics, Inc.
  • bioMérieux SA
  • Omega Diagnostics Group PLC
  • Hycor Biomedical, Inc.
  • Prota Therapeutics Pty Ltd
  • Intertek Group PLC
  • Merieux Nutrisciences Corporation
  • Eurofins Scientific
  • Symbio Laboratories
  • ALS Limited
  • Intertek Group PLC
  • Romer Labs Diagnostic GmbH
  • Asurequality Ltd
  • HAL Allergy B.V.